Indications: solid tumor, blood tumor

Description:

1. Independently developed domestic exclusive and urgently needed biological new drugs.

2. Clinically, it is used in combination with high-dose methotrexate for the treatment of osteosarcoma, lymphoma and acute lymphoblastic leukemia, so as to reduce the toxicity of chemotherapy and improve the treatment effect. At present, there is no effective solution in the treatment scheme of high-dose methotrexate. This product can quickly degrade methotrexate.

3. Phase III / II is under clinical development. Carry out clinical according to the number of combined and reduced cases in phase II / III, and apply for conditional approval for listing. It is planned to complete the clinical research in 2023 and apply for listing in 2024.